Navigation Links
Identified a new possible target to combat muscle wasting
Date:4/9/2014

In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.

DOR (Diabetes- and Obesity-regulated gene), also known as TP53INP2, is a protein involved in autophagy, a quality control process that ensures cells stay healthy. The researchers have found that increased DOR expression in the muscle of diabetic mice leads to enhanced autophagy, which in turn favours the loss of muscle mass in these animals.

The advantage of developing a DOR inhibitor is that autophagy, a process necessary to keep cells healthy, would not be completely blocked in the absence of this protein. DOR is not essential for autophagy, but acts more as an accelerator. Thus, the inhibition of DOR would only partially reduce autophagy as other molecules involved would exert their activity normally, thus maintaining the levels of autophagy in a beneficial range for cells.

"If we could treat patients with sarcopenia and cachexia, or people at risk of these conditions, using a drug to inhibitor DOR then we would be able to stop or prevent muscle wasting," explains the expert in diabetes and obesity Zorzano, head of the "Heterogenic and Polygenic Diseases" lab at IRB.

"We are showing pharmaceutical researchers a new possible therapeutic target for two diseases that seriously impair the quality of lives of those who suffer from them," says the scientist.

An answer to why type 2 diabetic patients lose less muscle than those with type 1

The study also solves a biomedical enigma related to diabetes. Physicians did not understand why patients with type 2 diabeteswho become resistance to insulin or have very low levels of this hormoneare able to maintain muscle mass or minimize muscle wasting compared to patients with type 1 diabeteswho do not produce insulinwho show a clear loss of muscle mass. The IRB researchers demonstrate that the repression of DOR in muscle cells of type 2 diabetic animals allows the maintenance of muscle mass.

"We interpret DOR repression, which occurs naturally, as an adaptation mechanism to preserve muscle mass and to maintain greater muscular strength in type 2 diabetics," explains David Sala, first author of the study, who has recently started a post-doctoral training period at Sanford-Burnham Medical Research Institute, in La Jolla, California.

Besides working with mice, the scientists have performed experiments on biopsies from skeletal muscle of patients with diabetes and patients resistant to insulin, thanks to collaboration with clinicians from the Universit Lyon 1, in France, and from the Medical University of Byalistok, Poland, also included among the authors.


'/>"/>

Contact: Sònia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert  

Related biology news :

1. Planarian genes that control stem cell biology identified
2. Hiding in plain sight, a new frog species with a weird croak is identified in New York City
3. Common North American frog identified as carrier of deadly amphibian disease
4. Culprit behind unchecked angiogenesis identified
5. Gene mutation identified as contributor to autism spectrum disorders
6. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
7. Researchers have identified a gene with a key role in neuronal survival
8. Like curry? New biological role identified for compound used in ancient medicine
9. Jack Spratt diabetes gene identified
10. A new indicator for breast cancer relapse identified
11. Parkinsons disease gene identified with help of Mennonite family: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Identified a new possible target to combat muscle wasting
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):
(Date:9/20/2017)... Baltimore, MD (PRWEB) , ... September 20, 2017 ... ... for digital pathology, and Huron Digital Pathology , a provider of whole ... Association’s 2017 Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... From industry ... therapy succeeded after standard medicine failed. Many of these people had lost all hope. ... Regression Free Download (pdf) , “Neil takes readers on ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading independent ... the opening of an office in Taipei, Taiwan. This new location allows RoviSys ... developing new relationships in the region. Located in the Neihu area of Taipei, ...
(Date:9/19/2017)... ... 19, 2017 , ... Participants of this educational webinar will ... Along with the advantages and disadvantages of ductless, filtered fume hoods, they will ... laboratory. , Attendees will learn from an industry expert about the different types ...
Breaking Biology Technology: